Tag: TUKYSA

Pfizer to acquire cancer drugmaker Seagen for $43bn in cash

Raghuram Kadari- March 16, 2023

American pharmaceutical and biotechnology company Pfizer has agreed to acquire cancer drugmaker Seagen (formerly Seattle Genetics) for $229 per share or $43 billion in cash, ... Read More

Seagen gets FDA accelerated approval for tucatinib, trastuzumab combo for colorectal cancer

Raghuram Kadari- January 21, 2023

American biotechnology company Seagen (formerly Seattle Genetics) has received accelerated approval from the US Food and Drug Administration (FDA) for the company’s oral drug Tukysa ... Read More

Seattle Genetics signs $4.4bn worth oncology deals with Merck

pharmanewsdaily- September 14, 2020

US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major ... Read More